FindTrial
Sign In

Double-Blind Trial of Miglitol in Type 2 Diabetic Patients Treated With Biguanide

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00334399
Enrollment
Unknown
Registered
2006-06-07
Start date
Unknown
Completion date
Unknown
Last updated
2008-10-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Keywords

alpa-glucosidase inhibitor,Biguanide

Brief summary

The purpose of this study is to evaluate the clinical efficacy and safety of Miglitol in patients with Type2 Diabetes Mellitus treated with Biguanide.

Interventions

DRUGMiglitol

Sponsors

Sanwa Kagaku Kenkyusho Co., Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
20 Years to 69 Years
Healthy volunteers
No

Inclusion criteria

* Type 2 diabetic patients treated with Biguanide * Criteria for postprandial plasma glucose and HbA1c are met

Exclusion criteria

* Type 1 diabetes * Patients treated with other antidiabetic drugs or Insulin

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026